Table 2.

Clinical trials of PD-L1 blockade combined with drugs targeting macrophages*.

Strategy	Cancer types	Clinical phase	Status/outcomes	Clinical identifier	Clinical Remark
Durvalumab + SNDX-6352	Unresectable ICC	2	Active, not recruiting	NCT04301778	20% ORR in 8 months Adverse events as abdominal pain, fatigue, increased AST
	Solid or Metastatic Tumor, Advanced Malignant Neoplasm	1	Completed	NCT03238027	No Results Posted
Avelumab + DCC-3014	Sarcoma	1	Active, not recruiting	NCT04242238	No Results Posted To find the safest dose of DCC-3014
Durvalumab + LY3022855	Solid Tumor	1	Completed	NCT02718911	Well tolerated Limited clinical activity
Atezolizumab + Emactuzumab	Solid Cancers	1	Completed	NCT02323191	Manageable safety profile with increased fatigue and skin rash A considerable ORR (12.5%) in ICB-experienced NSCLC patients

* The data source from https://www.clinicaltrials.gov and the latest update date is March 9, 2023. The meaning of abbreviations in this table are the same as in Table 1.